A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus

Jessica M. van Loben Sels; Luke W. Meredith; Stanislav V. Sosnovtsev; Miranda de Graaf; Marion P.G. Koopmans; Lisa C. Lindesmith; Ralph S. Baric; Kim Y. Green; Ian G. Goodfellow

doi:10.1016/j.jviromet.2021.114196

A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus

Jessica M. van Loben Sels, Luke W. Meredith, Stanislav V. Sosnovtsev, Miranda de Graaf, Marion P.G. Koopmans, Lisa C. Lindesmith, Ralph S. Baric, Kim Y. Green^*, Ian G. Goodfellow

^*Corresponding author for this work

Virology

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

161 Downloads (Pure)

Abstract

Background: Noroviruses are the most common cause of viral gastroenteritis worldwide, yet there is a deficit in the understanding of protective immunity. Surrogate neutralization assays have been widely used that measure the ability of antibodies to block virus-like particle (VLP) binding to histo-blood group antigens (HBGAs). However, screening large sample sets against multiple antigens using the traditional HBGA blocking assay requires significant investment in terms of time, equipment, and technical expertise, largely associated with the generation of purified VLPs. Methods: To address these issues, a luciferase immunoprecipitation system (LIPS) assay was modified to measure the norovirus-specific HBGA blockade activity of antibodies. The assay (designated LIPS-Blockade) was validated using a panel of well-characterized homotypic and heterotypic hyperimmune sera as well as strain-specific HBGA blocking monoclonal antibodies. Results: The LIPS-Blockade assay was comparable in specificity to a standard HBGA blocking protocol performed with VLPs. Using time-ordered patient sera, the luciferase-based approach was also able to detect changes in HBGA blocking titers following viral challenge and natural infection with norovirus. Conclusion: In this study we developed a rapid, robust, and scalable surrogate neutralization assay for noroviruses that circumvented the need for purified VLPs. This LIPS-Blockade assay should streamline the process of large-scale immunological studies, ultimately aiding in the characterization of protective immunity to human noroviruses.

Original language	English
Article number	114196
Number of pages	11
Journal	Journal of Virological Methods
Volume	297
DOIs	https://doi.org/10.1016/j.jviromet.2021.114196
Publication status	Published - Nov 2021

Bibliographical note

Funding
Funding for this work was provided by the Wellcome Trust [207498/Z/17/Z] (IGG); the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, NIH (KYG); COMPARE grant agreement N°643476 (MPGK) and MRACE grant 2017 (MdG); and National Institute of Allergy and Infectious Diseases, NIH grants R01 AI148260, R56 AI106006, U19 AI109761 CETR, and the Wellcome Trust [203268/Z/16/Z] (RSB).

Publisher Copyright:
© 2021 Elsevier B.V.

Access to Document

10.1016/j.jviromet.2021.114196

1-s2.0-S016609342100135X-mainFinal published version, 6.02 MB

Cite this

@article{85fba066987249709eaf7f47acfce259,

title = "A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus",

abstract = "Background: Noroviruses are the most common cause of viral gastroenteritis worldwide, yet there is a deficit in the understanding of protective immunity. Surrogate neutralization assays have been widely used that measure the ability of antibodies to block virus-like particle (VLP) binding to histo-blood group antigens (HBGAs). However, screening large sample sets against multiple antigens using the traditional HBGA blocking assay requires significant investment in terms of time, equipment, and technical expertise, largely associated with the generation of purified VLPs. Methods: To address these issues, a luciferase immunoprecipitation system (LIPS) assay was modified to measure the norovirus-specific HBGA blockade activity of antibodies. The assay (designated LIPS-Blockade) was validated using a panel of well-characterized homotypic and heterotypic hyperimmune sera as well as strain-specific HBGA blocking monoclonal antibodies. Results: The LIPS-Blockade assay was comparable in specificity to a standard HBGA blocking protocol performed with VLPs. Using time-ordered patient sera, the luciferase-based approach was also able to detect changes in HBGA blocking titers following viral challenge and natural infection with norovirus. Conclusion: In this study we developed a rapid, robust, and scalable surrogate neutralization assay for noroviruses that circumvented the need for purified VLPs. This LIPS-Blockade assay should streamline the process of large-scale immunological studies, ultimately aiding in the characterization of protective immunity to human noroviruses.",

author = "\{van Loben Sels\}, \{Jessica M.\} and Meredith, \{Luke W.\} and Sosnovtsev, \{Stanislav V.\} and \{de Graaf\}, Miranda and Koopmans, \{Marion P.G.\} and Lindesmith, \{Lisa C.\} and Baric, \{Ralph S.\} and Green, \{Kim Y.\} and Goodfellow, \{Ian G.\}",

note = "Funding Funding for this work was provided by the Wellcome Trust [207498/Z/17/Z] (IGG); the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, NIH (KYG); COMPARE grant agreement N°643476 (MPGK) and MRACE grant 2017 (MdG); and National Institute of Allergy and Infectious Diseases, NIH grants R01 AI148260, R56 AI106006, U19 AI109761 CETR, and the Wellcome Trust [203268/Z/16/Z] (RSB). Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = nov,

doi = "10.1016/j.jviromet.2021.114196",

language = "English",

volume = "297",

journal = "Journal of Virological Methods",

issn = "0166-0934",

publisher = "Elsevier",

}

TY - JOUR

T1 - A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus

AU - van Loben Sels, Jessica M.

AU - Meredith, Luke W.

AU - Sosnovtsev, Stanislav V.

AU - de Graaf, Miranda

AU - Koopmans, Marion P.G.

AU - Lindesmith, Lisa C.

AU - Baric, Ralph S.

AU - Green, Kim Y.

AU - Goodfellow, Ian G.

N1 - Funding Funding for this work was provided by the Wellcome Trust [207498/Z/17/Z] (IGG); the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, NIH (KYG); COMPARE grant agreement N°643476 (MPGK) and MRACE grant 2017 (MdG); and National Institute of Allergy and Infectious Diseases, NIH grants R01 AI148260, R56 AI106006, U19 AI109761 CETR, and the Wellcome Trust [203268/Z/16/Z] (RSB). Publisher Copyright: © 2021 Elsevier B.V.

PY - 2021/11

Y1 - 2021/11

N2 - Background: Noroviruses are the most common cause of viral gastroenteritis worldwide, yet there is a deficit in the understanding of protective immunity. Surrogate neutralization assays have been widely used that measure the ability of antibodies to block virus-like particle (VLP) binding to histo-blood group antigens (HBGAs). However, screening large sample sets against multiple antigens using the traditional HBGA blocking assay requires significant investment in terms of time, equipment, and technical expertise, largely associated with the generation of purified VLPs. Methods: To address these issues, a luciferase immunoprecipitation system (LIPS) assay was modified to measure the norovirus-specific HBGA blockade activity of antibodies. The assay (designated LIPS-Blockade) was validated using a panel of well-characterized homotypic and heterotypic hyperimmune sera as well as strain-specific HBGA blocking monoclonal antibodies. Results: The LIPS-Blockade assay was comparable in specificity to a standard HBGA blocking protocol performed with VLPs. Using time-ordered patient sera, the luciferase-based approach was also able to detect changes in HBGA blocking titers following viral challenge and natural infection with norovirus. Conclusion: In this study we developed a rapid, robust, and scalable surrogate neutralization assay for noroviruses that circumvented the need for purified VLPs. This LIPS-Blockade assay should streamline the process of large-scale immunological studies, ultimately aiding in the characterization of protective immunity to human noroviruses.

AB - Background: Noroviruses are the most common cause of viral gastroenteritis worldwide, yet there is a deficit in the understanding of protective immunity. Surrogate neutralization assays have been widely used that measure the ability of antibodies to block virus-like particle (VLP) binding to histo-blood group antigens (HBGAs). However, screening large sample sets against multiple antigens using the traditional HBGA blocking assay requires significant investment in terms of time, equipment, and technical expertise, largely associated with the generation of purified VLPs. Methods: To address these issues, a luciferase immunoprecipitation system (LIPS) assay was modified to measure the norovirus-specific HBGA blockade activity of antibodies. The assay (designated LIPS-Blockade) was validated using a panel of well-characterized homotypic and heterotypic hyperimmune sera as well as strain-specific HBGA blocking monoclonal antibodies. Results: The LIPS-Blockade assay was comparable in specificity to a standard HBGA blocking protocol performed with VLPs. Using time-ordered patient sera, the luciferase-based approach was also able to detect changes in HBGA blocking titers following viral challenge and natural infection with norovirus. Conclusion: In this study we developed a rapid, robust, and scalable surrogate neutralization assay for noroviruses that circumvented the need for purified VLPs. This LIPS-Blockade assay should streamline the process of large-scale immunological studies, ultimately aiding in the characterization of protective immunity to human noroviruses.

UR - http://www.scopus.com/inward/record.url?scp=85115628810&partnerID=8YFLogxK

U2 - 10.1016/j.jviromet.2021.114196

DO - 10.1016/j.jviromet.2021.114196

M3 - Article

C2 - 34019938

AN - SCOPUS:85115628810

SN - 0166-0934

VL - 297

JO - Journal of Virological Methods

JF - Journal of Virological Methods

M1 - 114196

ER -

A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this